Rapid Micro Biosystems
LOWELL, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, the leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the appointment of Gurinder Grewal as Senior Vice President of Strategy, reporting directly to the company’s CEO, Robert Spignesi.
In this newly created role, Grewal will be responsible for owning and executing on the company’s significant growth plans. Rapid Micro Biosystems has a truly unique market position in a very large and expanding global market opportunity. Grewal is responsible for driving the company’s global corporate strategy, marketing, product management, government affairs, and business development efforts to expand its capabilities as a significant and highly value-added partner to our customers. Grewal brings 20+ years of corporate and financial strategy, business development, and investment experience to RMB. He joins the company from Advent International, a highly successful global, growth-oriented private equity firm where, over 12 years, he grew his career from Principal to Partner & Managing Director. He led numerous private equity investments, where he closely partnered with management teams and developed strategies to drive significant organic and inorganic revenue and earnings growth. Prior to Advent, Grewal spent five years at Bain Capital where he built his career from Associate to Vice President. He started his career at Credit Suisse, where he was an Analyst on the investment banking team. Grewal holds an MBA from the Harvard Business School, and an HBA from the Richard Ivey School of Business at the University of Western Ontario in Canada.
"Rapid Micro Biosystems is at a critical time of growth. Gurinder brings a wealth of experience and will play a leading role in helping us expand our customer base and accelerating our growth," said Spignesi. "His contributions will be critical to achieving our global growth ambitions and reinforcing Rapid Micro Biosystems’ position as the leader in automated microbial quality control solutions."
"I am extremely excited to be joining Rapid Micro Biosystems at such an incredible time in the Company’s journey and to be part of a world-class management team," said Grewal. "I look forward to partnering with the team to achieve our ambition of significant long-term growth by focusing on our market and our customers."
We are excited to welcome Gurinder to the Executive Leadership Team.
About Rapid Micro Biosystems
Rapid Micro Biosystems (RMB) creates, sells, validates and services innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct™—the first and only growth-based system to automate rapid compendial QC Micro testing—ensures data integrity, compliance, and operational efficiencies driven by rapid methods and automation. RMB is dedicated to providing groundbreaking technology and products to support companies in their journey to achieve greater reliability, efficiency, and better predictability, ultimately providing higher quality products for improved patient outcomes. For more information, visit www.rapidmicrobio.com. Follow RMB at @rapidmicrobio or LinkedIn.
For more information contact:
Courtney Makolandra
Rapid Micro Biosystems
Email: CMakolandra@rapidmicrobio.com
Tel. 978.349.3200
Fax. 978.349.2065
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
BIK26.6.2025 06:00:00 CEST | Press release
BIK Data Analysis indicates: Including BNPL Transaction Data in Credit History Could Help Almost Every Second “Thin-file Customer” Improve their Creditworthiness
Alvotech25.6.2025 22:45:00 CEST | Press release
Main Results of 2025 Annual and Extraordinary General Meeting
Teva Pharmaceutical Industries Ltd25.6.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
Golar LNG25.6.2025 22:15:07 CEST | Press release
Golar LNG Limited Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2030
DBV Technologies S.A.25.6.2025 22:15:00 CEST | Press release
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom